Enzene Biosciences Limited raises US$50 million from Eight Roads Ventures and Impresa Management LLC
EY acted as the exclusive financial advisor to Enzene Biosciences Limited on its fund raise of US$50 million from Eight Roads Ventures and Impresa Management LLC. Enzene will leverage the fresh funds to enhance its manufacturing capabilities and drive expansion in its core markets of India and the US.
Enzene, a subsidiary of Alkem laboratories, engages in research, development, manufacturing, and out licensing of biosimilar product. The Company was incorporated in 2006 and is based in Pune, India.
Eight Roads Ventures is a venture capital and private equity firm based in London, United Kingdom. The firm invests in the technology sector with a focus on healthcare, IT, communications, financial services, fintech and consumer technology.
Impresa Management LLC is a venture capital firm based in Boston, Massachusetts. It typically invests in healthcare, therapeutics, medtech and healthcare technology & services.
Eight Roads’ investment in Enzene endorses its capability to manufacture and deliver innovative and cost effective biosimilars globally.The investment will enable Enzene fulfil its mission of becoming a global biologics company and deliver better health outcomes
Amit Gupta
Partner, Investment Banking Advisory, EY
